Quantum Private Wealth LLC Sells 1,000 Shares of Zoetis Inc. (NYSE:ZTS)

Quantum Private Wealth LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 14.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,064 shares of the company’s stock after selling 1,000 shares during the quarter. Quantum Private Wealth LLC’s holdings in Zoetis were worth $1,197,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Blue Bell Private Wealth Management LLC raised its stake in shares of Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares during the last quarter. Evermay Wealth Management LLC raised its stake in shares of Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares during the last quarter. Worth Asset Management LLC purchased a new position in shares of Zoetis in the first quarter worth $26,000. Finally, Moisand Fitzgerald Tamayo LLC raised its stake in shares of Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after purchasing an additional 96 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the transaction, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,209 shares of company stock valued at $408,453 over the last 90 days. Company insiders own 0.15% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research reports. Barclays upped their price objective on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. Jefferies Financial Group reiterated a “buy” rating and set a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Piper Sandler reiterated an “overweight” rating and set a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, The Goldman Sachs Group upped their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $221.75.

Zoetis Stock Performance

ZTS traded up $3.25 during midday trading on Wednesday, reaching $153.02. The company had a trading volume of 4,967,617 shares, compared to its average volume of 3,610,045. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The business has a 50-day moving average of $178.25 and a two-hundred day moving average of $180.59. The company has a market cap of $69.99 billion, a P/E ratio of 30.18, a P/E/G ratio of 2.29 and a beta of 0.85. Zoetis Inc. has a 1 year low of $148.48 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.15 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.13%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.